Psychemedics Corporation (PMDI)

Market Cap	11.08M
Revenue (ttm)	20.26M
Net Income (ttm)	-3.00M
Shares Out	5.89M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,400
Open	1.750
Previous Close	1.850
Day's Range	1.750 - 1.940
52-Week Range	1.110 - 3.949
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 3, 2025

About Psychemedics

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabino...

• Industry: Medical Laboratories
• Founded: 1986
• Employees: 116
• Stock Exchange: OTCMKTS
• Ticker Symbol: PMDI

Financial Performance

In 2023, Psychemedics's revenue was $22.10 million, a decrease of -12.45% compared to the previous year's $25.24 million. Losses were -$4.15 million, 283.2% more than in 2022.